Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells
Open Access
- 30 September 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 8 (4) , zcag030
Abstract
High-grade serous ovarian carcinoma (HGSOC) recurs in most patients despite initial responses to chemotherapy and poly(ADP-ribose) polymerase inhibition. A leading explanation for the high rates of recurrence is the presence of minimal residual disease (MRD) comprised of drug-tolerant persister (DTP) cells that survive therapy through reversible epigenetic reprogramming. DTPs have various adaptations that enable them to tolerate therapy and eventually develop into resistant clones, including quiescence, metabolic and hypoxic stress responses, epithelial-mesenchymal plasticity, and immune evasion. Here, we discuss evidence from ovarian cancer of epigenetic mechanisms that coordinate DTP phenotypes, including DNA methylation, histone post-translational modifications, enhancer rewiring, and transcription factor gene-regulatory networks. Based on therapeutic vulnerabilities identified from increased resolution of DTPs, we highlight epigenetic therapies that are currently in clinical trials aimed at depleting MRD to delay or prevent relapse in HGSOC. Finally, we outline emerging technologies that have the potential to detect and monitor persister states in patients, including single-cell transcriptomic and epigenomic profiling, long-read sequencing, and spatial mapping of tumor biopsies.Keywords
Funding Information
- Mayo Clinic (P50 CA136393)
- Department of Defense Ovarian Cancer
- Ovarian Cancer Academy (W81XWH2110475)
- Department of Defense Ovarian Cancer Research Program (HT94252510458)
- Canadian Institutes of Health Research (236-2024-2025-Q2-00473)
- Foundation for Women Wellness
- AACR Scholar-in-Training award
- Mayo Medical Scientist Training Program (T32 GM145408)
- Paul Calabresi Program in Clinical/Translational Research
- Mayo Clinic Comprehensive Cancer Center (K12CA090628)
- V Foundation for Cancer Research (V2026-006)
This publication has 116 references indexed in Scilit:
- Pan‐cancer proteogenomic landscape of whole‐genome doubling reveals putative therapeutic targets in various cancer typesClinical and Translational Medicine, 2024
- Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinomaCancer Cell, 2023
- The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial CellsCancer Cell, 2020
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid TumorsCancer Cell, 2019
- Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug ExposureCancer Cell, 2017
- Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh CellsCancer Cell, 2013
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinomaCancer, 2006
- Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayersClinical & Experimental Metastasis, 2005